what is kisspeptin: Frequently asked questions

Both are kisspeptin. The number indicates the amino acid length of the specific isoform used. Kisspeptin-10 is the shortest active fragment (10 amino acids), while kisspeptin-54 is the full-length mature peptide cleaved from the KISS1 precursor. All isoforms share the same C-terminal decapeptide that drives receptor binding, so biological activity is equivalent at equimolar doses. The choice depends on study design: kisspeptin-10 is easier to synthesize and more stable in solution, while kisspeptin-54 has a longer in vivo half-life (28 minutes vs 4 minutes), making it better suited for sustained signaling studies. Neither is 'better'. They're the same signaling molecule at different fragment lengths.

The most common cause is peptide degradation from improper storage or reconstitution. Kisspeptin is highly susceptible to proteolytic cleavage by serum peptidases. If the lyophilized powder was stored above −20°C or the reconstituted solution wasn't used within 48 hours, bioactivity drops precipitously even if the solution appears clear. Verify purity via mass spectrometry and HPLC before assuming the assay conditions are at fault. Secondary causes include incorrect receptor expression in the cell line (KISS1R must be present at sufficient density) or serum interference in the assay medium. Kisspeptin degrades rapidly in the presence of proteases, so assays should use serum-free medium or include protease inhibitors.

Metastin is the original name given to kisspeptin-54 when it was first identified as a metastasis suppressor in melanoma cells in 1996. The reproductive function wasn't discovered until 2003, at which point the molecule was renamed kisspeptin to reflect its role in reproductive physiology. Both names refer to the same 54-amino-acid peptide. Current literature uses 'kisspeptin' almost exclusively, but older papers (pre-2005) and some cancer research still use 'metastin.' If you encounter metastin in a protocol, it's referring to kisspeptin-54. Treat dosing and handling identically.

Use it. But adjust your dosing calculations. Both peptides activate GPR54 with equivalent potency when dosed on a molar basis, not a mass basis. If your protocol calls for 1.0 nmol/kg kisspeptin-10 (molecular weight ~1,302 Da), the equivalent dose of kisspeptin-54 (molecular weight ~6,043 Da) is 4.64 mg/kg per nanomole. The mistake most researchers make is dosing by weight without accounting for the 4.6× molecular weight difference, which results in severe underdosing. Recalculate based on molar equivalence, verify concentration via UV spectrophotometry at 280 nm (both contain tryptophan residues), and proceed. The primary downside is reduced shelf life once reconstituted. Kisspeptin-54 degrades faster in solution, so prepare smaller aliquots.

This indicates pH incompatibility or excessive ionic strength. Kisspeptin-10 is most soluble at neutral to slightly acidic pH (6.0–7.4) in low-salt buffers. If precipitation occurs in PBS or saline, switch to sterile water or 10 mM acetic acid, which maintains solubility without compromising peptide stability. Gently warm the vial to 25–30°C (never above 37°C) and vortex briefly. Most precipitates redissolve within 2–3 minutes. If cloudiness persists, the peptide may have undergone oxidative damage during storage (methionine oxidation at position 48 is common). Run a quick potency check via mass spectrometry or discard and replace. Oxidized peptides show 40–60% reduced receptor binding.

Switch to pulsatile dosing. Continuous kisspeptin exposure desensitizes GPR54 receptors within 8–12 hours, abolishing LH response entirely. A phenomenon documented in multiple primate studies. Effective chronic protocols require intermittent bolus injections at 60–90 minute intervals, mimicking the physiological GnRH pulse generator. If continuous infusion is unavoidable (e.g., automated pumps in large animal models), reduce the infusion rate to 10–15% of the acute bolus dose and monitor LH levels daily. Expect diminishing returns after 48–72 hours even with dose adjustments. Tachyphylaxis is the limiting factor in long-term kisspeptin research, not peptide stability.